Serious adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Serious adverse events · hospitalised adults at nutritional risk
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Serious adverse events ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in serious adverse events ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with episodic tension‐type headache
1 finding from 1 review
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders
1 finding from 1 review
Serious adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in serious Adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · induction of remission in Crohn's disease
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · newly diagnosed patients with myelodysplastic syndromes
1 finding from 1 review
Serious adverse events · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
Serious adverse events · people with asthma
1 finding from 1 review
no estimate extracted
2013 participants
Very low
Serious adverse events · patients with chronic pancreatitis and pancreatic pain
Pregabalin showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review